Levaquin[R] receives FDA approval for treatment of chronic bacterial prostatitis.(New Products)(Brief Article)
Publication: Urologic Nursing
Publication Date: 01-APR-04
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
The U.S. Food and Drug Administration (FDA) has approved Levaquin[R] (levofloxacin) Tablets/Injection and Levaquin[R] (levofloxacin in 5% dextrose) Injection for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis or Staphylococcus epidermidis. Chronic bacterial prostatitis is a recurrent or persistent infection of the prostate gland and...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
